US EditionPublished • loading... • Updated
Organon pays $27.5M to agree to license Sebela Pharmaceuticals’ IUD device
Summary by ROI-NJ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Organon pays $27.5M to agree to license Sebela Pharmaceuticals’ IUD device
Global health care company Organon, based out of Jersey City, agreed Feb. 23 to pay $27.5 million to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration approval of MIUDELLA’s alternate supply chain entities and ce…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
